Continuous glucose monitoring-guided management of capivasertib-associated hyperglycemia: A case series of three patients
Abstract
Capivasertib, an AKT inhibitor for advanced breast cancer, frequently induces hyperglycemia. We present a case series of three patients (two without pre-existing diabetes) monitored with continuous glucose monitoring. Hyperglycemia developed within 2 weeks in all cases. Continuous glucose monitoring visualized glycemic fluctuations synchronized with the "4-days-on, 3-days-off" cycle. A patient with low baseline homeostatic model assessment for β-cell function and higher insulin resistance required insulin, whereas a patient with relatively preserved insulin action was managed with oral glucose-lowering agents. These hypothesis-generating observations suggest that pretreatment metabolic assessment might assist in preliminary risk stratification.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.